Visara, Inc.
Clinical trials sponsored by Visara, Inc., explained in plain language.
-
New eye injection targets two causes of vision loss in wet AMD
Disease control CompletedThis early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were t…
Phase: PHASE1, PHASE2 • Sponsor: Visara, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New Dual-Action eye drug shows promise in early trial for Diabetes-Related vision loss
Disease control CompletedThis early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check saf…
Phase: PHASE1 • Sponsor: Visara, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC